Post Profile

Xarelto (Rivaroxaban) Approved By FDA For Non-Valvular Atrial Fibrillation Patients

Xarelto (rivaroxaban), an anti-clotting medication, has been approved by the FDA for patients with non-valvular atrial fibrillation to reduce stroke risk. Xarelto, a Factor Xa inhibitor, acts at a crucial point in the blood-clotting process and stops the formation of blood clots. Its principal advantage over other anti-clotting medications (anticoagulants) is that it does not need such close monitoring or dosage adjustments.
read more

See more about: Atrial Fibrillation

Related Posts

Stroke Prevention Improves In Cases Of Atrial Fibrillation - ENS 2012

Health : Medical News Today

Stroke: Better prevention in cases of atrial fibrillation, minimally invasive surgery for blood clots in the brain. Better drugs for stroke prevention for patients with atrial fibrillation, good results in the removal of blood clots...

For Atrial Fibrillation Patients, Rivaroxaban Has Less Risk Of Brain Bleeding In Patients At High Risk For Stroke

Health : Medical News Today

For patients with a type of irregular heart beat called atrial fibrillation (AF), a new anti-clotting drug might be better at preventing clot-related strokes while minimizing the risk of causing a bleeding stroke. The research was p...

Non-Valvular Artial Fibrillation Drug Xarelto® (Rivaroxaban), Studies Investigate Benefits

Health : Medical News Today

Patients with Atrial Fibrillation (AF) who undergo cardioversion or catheter ablation therapy are at particular risk of stroke and require effective anticoagulation before and after these procedures. Xarelto is indicated for the pre...

Pradaxa (dabigatran Etexilate) For Stroke Prevention In Patients With Atrial Fibrillation Approved By FDA

Health : Medical News Today

Pradaxa (dabigatran etexilate), an anticoagulant, has been approved in capsule form for the prevention of blood clots and strokes in individuals with atrial fibrillation by the US Food and Drug Administration (FDA). People with atri...

Xarelto (Rivaroxaban) Recommended For Patients With Non-valvular Atrial Fibrillation, USA

Health : Medical News Today

Anticoagulant Xarelto (rivaroxaban) has been recommended by the FDA's Cardiovascular Renal Drugs Advisory Committee for the prevention of systemic embolism and stroke in patients with non-valvular AF (atrial fibrillation). The Commi...


Copyright © 2016 Regator, LLC